Proactive Investors - Run By Investors For Investors

ReNeuron's Michael Hunt on 'very significant' exosome therapy data

Michael Hunt, CFO for ReNeuron Group Plc (LON:RENE), explains to Proactive their latest research which has been presented at a conference in Canada - highlighting the ability of their exosome therapy candidate to target specific organs of the body.

Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full RENE profile View Profile

ReNeuron Group PLC Timeline

December 19 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use